Home > Insider Trading > Filing (0001725160-22-000015)

Filing Details

Accession Number:: 0001725160-22-000015
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-01-20 19:15:07
Reporting Period:: 2022-01-18

Accepted Time:: 2022-01-20 19:15:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	Pharmaceutical Preparations (2834)	823607803

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807910	Dimitris Voliotis	C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway, Suite 1710 New York NY 10018	Svp, Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-01-18	10,000	$18.00	16,250	No	4	M	Direct
Common Stock	Disposition	2022-01-18	3,409	$61.70	12,841	No	4	S	Direct
Common Stock	Disposition	2022-01-18	3,294	$62.34	9,547	No	4	S	Direct
Common Stock	Disposition	2022-01-18	1,997	$63.48	7,550	No	4	S	Direct
Common Stock	Disposition	2022-01-18	1,300	$64.66	6,250	No	4	S	Direct
Common Stock	Acquisiton	2022-01-19	10,000	$18.00	16,250	No	4	M	Direct
Common Stock	Disposition	2022-01-19	7,889	$60.55	8,361	No	4	S	Direct
Common Stock	Disposition	2022-01-19	1,556	$61.51	6,805	No	4	S	Direct
Common Stock	Disposition	2022-01-19	555	$62.24	6,250	No	4	S	Direct
Common Stock	Acquisiton	2022-01-20	10,000	$18.00	16,250	No	4	M	Direct
Common Stock	Disposition	2022-01-20	8,343	$60.52	7,907	No	4	S	Direct
Common Stock	Disposition	2022-01-20	1,657	$61.21	6,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Disposition	2022-01-18	10,000	$0.00	10,000	$18.00
Common Stock	Stock Option	Disposition	2022-01-19	10,000	$0.00	10,000	$18.00
Common Stock	Stock Option	Disposition	2022-01-20	10,000	$0.00	10,000	$18.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
144,949	2030-03-25	No	4	M	Direct
134,949	2030-03-25	No	4	M	Direct
124,949	2030-03-25	No	4	M	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.97 to $61.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.98 to $62.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $63.18 to $64.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.23 to $65.19. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.07 to $61.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.09 to $61.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $62.15 to $62.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.00 to $60.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.01 to $61.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests and becomes exercisable as to 25% of the shares on March 25, 2021 and vests in equal monthly installments thereafter until March 25, 2024.